v3.25.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating expenses:        
Research and development, net of grants $ 4,759 $ 3,513 $ 8,976 $ 7,239
General and administrative, net of grants 2,703 2,168 5,044 4,669
Total operating expenses 7,462 5,681 14,020 11,908
Loss from operations (7,462) (5,681) (14,020) (11,908)
Other income, net 318 325 574 513
Net loss $ (7,144) $ (5,356) $ (13,446) $ (11,395)
Net loss per common share - basic (in dollars per share) $ (0.12) $ (0.1) $ (0.23) $ (0.21)
Net loss per common share - diluted (in dollars per share) $ (0.12) $ (0.1) $ (0.23) $ (0.21)
Weighted average common shares outstanding - basic (in shares) 59,244 55,021 59,240 53,612
Weighted average common shares outstanding - diluted (in shares) 59,244 55,021 59,240 53,612

Source